ConforMIS (CFMS) Receives Consensus Rating of “Hold” from Brokerages

Shares of ConforMIS (NASDAQ:CFMS) have been assigned a consensus rating of “Hold” from the nine ratings firms that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $5.13.

CFMS has been the subject of several recent research reports. BTIG Research raised shares of ConforMIS from a “neutral” rating to a “buy” rating and set a $4.00 target price for the company in a report on Wednesday, December 20th. JPMorgan Chase lowered shares of ConforMIS from a “neutral” rating to an “underweight” rating in a report on Tuesday, January 2nd. Zacks Investment Research lowered shares of ConforMIS from a “hold” rating to a “sell” rating in a report on Wednesday, January 24th. Oppenheimer set a $4.00 target price on shares of ConforMIS and gave the company a “buy” rating in a report on Thursday, February 8th. Finally, Canaccord Genuity cut their target price on shares of ConforMIS from $5.00 to $4.00 and set a “hold” rating for the company in a report on Thursday, February 8th.

Shares of NASDAQ:CFMS remained flat at $$1.38 during trading on Wednesday. 166,372 shares of the stock traded hands, compared to its average volume of 619,780. The company has a debt-to-equity ratio of 0.64, a quick ratio of 4.70 and a current ratio of 5.41. The stock has a market cap of $83.96, a price-to-earnings ratio of -1.13 and a beta of 1.00. ConforMIS has a 52-week low of $1.15 and a 52-week high of $5.98.

ConforMIS (NASDAQ:CFMS) last posted its earnings results on Wednesday, February 7th. The medical instruments supplier reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.03. The firm had revenue of $20.80 million during the quarter, compared to analyst estimates of $20.07 million. ConforMIS had a negative net margin of 68.59% and a negative return on equity of 85.24%. The business’s quarterly revenue was down 4.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.37) EPS. equities research analysts forecast that ConforMIS will post -0.86 EPS for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Two Sigma Investments LP purchased a new stake in ConforMIS in the 4th quarter worth $130,000. Deutsche Bank AG increased its holdings in ConforMIS by 43.5% in the 4th quarter. Deutsche Bank AG now owns 120,849 shares of the medical instruments supplier’s stock worth $286,000 after acquiring an additional 36,634 shares in the last quarter. Renaissance Technologies LLC increased its holdings in ConforMIS by 627.0% in the 4th quarter. Renaissance Technologies LLC now owns 346,800 shares of the medical instruments supplier’s stock worth $825,000 after acquiring an additional 299,100 shares in the last quarter. Prosight Management LP purchased a new stake in ConforMIS in the 4th quarter worth $952,000. Finally, ARK Investment Management LLC increased its holdings in ConforMIS by 44.0% in the 4th quarter. ARK Investment Management LLC now owns 390,564 shares of the medical instruments supplier’s stock worth $930,000 after acquiring an additional 119,355 shares in the last quarter. 22.98% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “ConforMIS (CFMS) Receives Consensus Rating of “Hold” from Brokerages” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/09/conformis-cfms-receives-consensus-rating-of-hold-from-brokerages.html.

ConforMIS Company Profile

ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.

Analyst Recommendations for ConforMIS (NASDAQ:CFMS)

Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply